News
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...
Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...
The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.
By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval ...
Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.
Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy ...
Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...
The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...
When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback